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ABSTRACT
The minor capsid protein of human BK polyomavirus (BKPyV), VP2, and its N-terminally truncated form, VP3, are both impor-
tant for viral entry. The closely related simian virus 40 (SV40) reportedly produces an additional truncated form of VP2/3, de-
noted VP4, apparently functioning as a viroporin promoting progeny release. The VP4 open reading frame is conserved in some
polyomaviruses, including BKPyV. In this study, we investigated the role of VP4 in BKPyV replication. By transfecting viral ge-
nomes into primary human renal proximal tubule epithelial cells, we demonstrated that unaltered BKPyV and mutants with
start codon substitutions in VP4 (VP2M229I and VP2M229A) abolishing putative VP4 production were released at the same
level to supernatants. However, during infection studies, VP2M229I and VP2M229A exhibited 90% and 65% reduced infectivity,
respectively, indicating that isoleucine substitution inadvertently disrupted VP2/3 function to the detriment of viral entry, while
inhibition of VP4 production during late infection was well tolerated. Unexpectedly, and similarly to BKPyV, wild-type SV40
and the corresponding VP4 start codon mutants (VP2M228I and VP2M228A) transfected into monkey kidney cell lines were also
released at equal levels. Upon infection, only the VP2M228I mutant exhibited reduced infectivity, a 43% reduction, which also
subsequently led to delayed host cell lysis. Mass spectrometry analysis of nuclear extracts from SV40-infected cells failed to iden-
tify VP4. Our results suggest that neither BKPyV nor SV40 require VP4 for progeny release. Moreover, our results reveal an im-
portant role in viral entry for the amino acid in VP2/VP3 unavoidably changed by VP4 start codon mutagenesis.
IMPORTANCE
Almost a decade ago, SV40 was reported to produce a late nonstructural protein, VP4, which forms pores in the nuclear mem-
brane, facilitating progeny release. By performing transfection studies with unaltered BKPyV and SV40 and their respective
VP4-deficient mutants, we found that VP4 is dispensable for progeny release, contrary to the original findings. However, infec-
tion studies demonstrated a counterintuitive reduction of infectivity of certain VP4-deficient mutants. In addition to the isoleu-
cine-substituted SV40 mutant of the original study, we included alanine-substituted VP4-deficient mutants of BKPyV
(VP2M229A) and SV40 (VP2M228A). These revealed that the reduction in infectivity was not caused by a lack of VP4 but rather
depended on the identity of the single amino acid substituted within VP2/3 for VP4 start codon mutagenesis. Hopefully, our re-
sults will correct the longstanding misconception of VP4’s role during infection and stimulate continued work on unraveling the
mechanism for release of polyomavirus progeny.
Currently there are 13 known species of human polyomavi-ruses, and of these at least four are associated with diseases
mainly affecting immunocompromised patients. BK polyomavi-
rus (BKPyV) is the chief agent of polyomavirus-associated ne-
phropathy (PyVAN) and polyomavirus-associated hemorrhagic
cystitis (PyVHC), while JC polyomavirus (JCPyV) causes progres-
sive multifocal leukoencephalopathy (PML). Merkel cell polyo-
mavirus is associated with the rare but aggressive skin cancer
Merkel cell carcinoma, and trichodysplasia spinulosa-associated
polyomavirus causes the proliferative skin disease giving rise to its
name. Although still not completely understood, a major compo-
nent of the pathogenesis of PyVAN, PyVHC, and PML is thought
to be the high-level lytic viral replication in renal tubular epithelial
cells (1), bladder epithelial cells (2), and oligodendrocytes (3, 4),
respectively.
Polyomaviruses are nonenveloped, spherical viruses with a di-
ameter of about 45 nm (5, 6). The capsid has icosahedral symme-
try, and the outer surface consists of the major capsid protein VP1
arranged in 72 pentamers. Inside the capsid, associated with the
central cavity of each VP1 pentamer is one copy of either VP2 or
VP3, the minor capsid proteins (7). These proteins bind the VP1
pentamers of the capsid to the circular double-stranded DNA ge-
nome. The genome can be functionally divided into an early re-
gion, late region, and noncoding control region (NCCR) (8). The
early region encodes the regulatory large and small tumor antigens
(LTag and sTag, respectively) and various truncated variants,
while the late region encodes the capsid proteins VP1, VP2, and
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VP3. In addition, the late region of JCPyV, BKPyV, and the closely
related monkey polyomavirus, simian virus 40 (SV40), encodes
agnoprotein, a nonstructural protein with incompletely charac-
terized functions (8). In 2007, Daniels and colleagues reported
that SV40 produces another late nonstructural protein, denoted
VP4 (9). Interestingly, this small protein (13.9 kDa) was expressed
24 h after the other late proteins and is suggested to play a role in
progeny release (9). The third genome region, the NCCR, con-
tains the origin of replication, the early and late promoter, and
enhancer sequences. During high-level virus replication, the
NCCR is commonly rearranged. This frequently leads to an in-
creased expression of LTag, which in turn causes enhanced viral
replication (8, 10, 11).
Although the replication cycle of different polyomaviruses has
been extensively studied, the process of progeny release is still
unclear. Recently, several viruses have been proposed to produce
viroporins, small hydrophobic proteins that oligomerize in host
cell membranes, forming hydrophilic pores affecting several steps
in the replication cycle, including progeny release (reviewed in
reference 12). Four viroporins have been described for polyoma-
viruses: JCPyV agnoprotein (13), SV40 VP2 and VP3 (14), and
SV40 VP4 (15, 16).
During SV40 replication, VP4 alone or in cooperation with
VP2 and/or VP3 has been suggested to permeabilize the nuclear
membrane, thereby disturbing the ionic homeostasis and en-
hancing progeny release (15, 17). The VP4 start codon, like that
of VP3, lies within the sequence of VP2; thus, VP2, VP3, and
VP4 share a C terminus. Polyclonal antibodies targeting the
C-terminal part of VP2 or VP3 therefore should detect VP4 if it
is produced, and this was in fact how SV40 VP4 expression was
first demonstrated (9). Subsequent characterization of VP4 has
been done mainly by biochemical approaches using recombi-
nant VP4 (15–17).
Like SV40, the BKPyV genome has additional open reading
frames (ORFs) downstream and in frame with the VP2 and VP3
ORFs, potentially encoding a BKPyV VP4 and two even smaller
proteins, the putative VP5 and VP6, that all share a C terminus
with VP2 and VP3 (Fig. 1A). The amino acid sequence of the C
terminus contains important features, including a VP1-binding
region, a DNA-binding region, and a nuclear localization signal
(NLS) (Fig. 1A). Our initial aim was to investigate whether
BKPyV-infected primary human renal proximal tubular epithelial
cells (RPTECs) produce VP4 during a productive infection and to
study a possible effect on virion release. Here, we report that
BKPyV is not dependent on VP4 for effective progeny release.
Instead, the two VP4-deficient BKPyV mutants were found to be
defective in entry events, and this phenotype was dependent on
the identity of the amino acid in VP2 and/or VP3 unavoidably
changed during the substitution of the initial methionine of VP4.
To investigate the effect on infectivity for SV40 VP4-deficient mu-
tants, we repeated our experiments using SV40 as in the original
VP4 report. Surprisingly, we obtained results similar to those for
BKPyV. SV40 progeny release did not depend on VP4 expression,
and entry was affected by one amino acid change in VP2 and/or
VP3. Moreover, we were not able to detect VP4 in SV40-infected
cells despite searches using tandem mass spectrometry (MS/MS).
Our results cast doubt on the suggested role of VP4 in the polyo-
mavirus replication cycle.
MATERIALS AND METHODS
Viruses, plasmids, and mutagenesis. All BKPyV experiments were per-
formed with BKPyV Dunlop (ATCC 45025) (wild type [WT]) or BKPyV
WW (WW WT) and virus with mutation of the start codon of VP2, VP3,
VP4, or both VP2 and VP3 (Table 1). All SV40 experiments were per-
formed with strain 776 and virus with start codon mutations of VP4
(Table 1). All mutants were created by long PCR of pBKV (34-2) (ATCC
45025) (18), pBKV WWT (19), or pWTSV40 JL (20) using overlapping
primers that targeted the ATG start codon (Table 1) and the high-fidelity
Phusion polymerase (M0530S; New England BioLabs) according to the
manufacturer’s instructions as previously described (21). Sanger sequenc-
ing confirmed successful mutagenesis. BKPyV VP1, VP3, and VP4 expres-
sion plasmids with N-terminal enhanced green fluorescent protein
(eGFP) tags were created by gateway cloning using a pDEST-EGFP-C1
destination vector (22) kindly provided by Ole Morten Seternes, UiT The
Arctic University of Norway. Codon-optimized SV40 VP4 expression
plasmid with C-terminal eGFP tag was codon optimized for human cells
by GenScript.
Cells. The African green monkey kidney cell lines Vero (ATCC CCL-
81) and BS-C-1 (ATCC CCL-26) were cultured in Dulbecco’s modified
Eagle’s medium (D5671; Sigma-Aldrich) supplemented with 10% fetal
bovine serum (FBS) and 1 GlutaMAX-I (no. 35050; Thermo Fisher
Scientific). The African green monkey kidney cell line CV-1 (ATCC CCL-
70) and the SV40-LTag-transformed COS-7 (ATCC CRL-1651) cells were
cultured in Dulbecco’s modified Eagle’s medium supplemented with 5%
FBS and 1 GlutaMAX-I. HeLa cells (ATCC CCL-2) were cultured in
modified Eagle’s medium (M2279; Sigma-Aldrich) supplemented with
10% FBS and 1 GlutaMAX-I. Primary human renal proximal tubular
epithelial cells (RPTECs; ScienCell Research Laboratories) were cultured
in renal epithelial growth medium (REGM; Lonza) containing 0.5% FBS
and used at passage 4. All cells were cultivated in a humidified 5% CO2
incubator at 37°C.
Transfections. Transfection of RPTECs was performed by electropo-
ration using the Neon transfection system (Thermo Fisher Scientific). In
short, 0.1 g of BamHI-linearized and ligated plasmid was transfected
into 2.5  104 cells, and electroporation was performed in 10-l electro-
poration tips and with 1 pulse at 1,400 V and 20-ms pulse width. Trans-
fected cells were seeded in plates with REGM without antibiotics. The day
after transfection, the cell medium was replaced with fresh complete
REGM. Transfection of CV-1, BS-C-1, Vero, and HeLa cells was per-
formed with Lipofectamine 2000 (Thermo Fisher Scientific) according to
the manufacturer’s instructions. In short, for transfection in wells in a
48-well plate, 0.1 g linearized and ligated plasmid was mixed with the
empty plasmid vector pUC19 to get a final DNA concentration of 0.5 g
per transfection. The ratio of DNA (micrograms) to Lipofectamine 2000
(microliters) was 1:2 for CV-1 and Vero cells, 1:1.5 for BS-C-1 cells, and
1:3 for HeLa cells. The cell medium containing the transfection mix was
removed and fresh medium was added at 4 to 6 h posttransfection (hpt).
For mock transfections, 0.5 g pUC19 was used alone.
Viral infections. Supernatants from BKPyV-transfected RPTECs and
Vero cells or SV40-transfected CV-1 and BS-C-1 cells were diluted 1:2 in
fresh complete medium and used to infect RPTECs and CV-1 cells, re-
spectively. All infections were carried out for 2 h before the infectious
inoculum was removed, cells were washed once with 1 phosphate-buff-
ered saline (PBS), and complete medium was added.
Immunofluorescence staining, microscopy, and digital image pro-
cessing. Infected and transfected cell monolayers were fixed with 4%
paraformaldehyde in PBS for 10 min and permeabilized with 100% meth-
anol for 10 min, and then immunofluorescence was performed as de-
scribed earlier (23). The primary antibodies used were mouse monoclonal
SV40 LTag (Ab-2; 1:100; Calbiochem), SV40 LTag (Pab419; 1:100; Santa
Cruz Biotechnology), BKPyV VP1 (4942; 2.8 g/ml; Virostat Inc.), and
rabbit polyclonal antiserum directed against BKPyV agnoprotein (1:
1,000) (24), BKPyV VP1 (1:1,000) (25), SV40 VP1 (Ab53977; 1:1,000,
Abcam), and SV40 VP2/3 (Ab53983; 1:1,000; Abcam). The secondary
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FIG 1 BKPyV minor capsid proteins are recognized by SV40 VP2/3 antiserum. (A) Schematic overview of BKPyV minor capsid protein VP2 and its confirmed
and putative truncated variants. Annotated regions and motifs are derived from the UniProtKB database, accession numbers P03093 and P03094, and the VP4
hydrophobic domain is annotated by similarity to SV40 VP4. (B) Immunofluorescence labeling of RPTECs at 1 dpt with the eGFP-VP4 expression plasmid, using
the SV40 VP2/3 antisera (red) and the DNA stain Draq5 (blue). The level of eGFP expression is indicated in parentheses as weak (w) or strong (s). As a positive
and negative control for the SV40 VP2/3 antiserum, RPTECs were transfected with eGFP-VP3 and eGFP, respectively. In addition, cells were transfected with
eGFP-VP1 plasmid and immunofluorescence labeling was performed using the BKPyV VP1 antisera (red). Images were acquired by confocal microscopy with
a 40 objective and with a 2 zoom. (C) Western blot of HeLa cell lysate harvested at 1 dpt with the indicated expression plasmids. The membrane was probed
with a GFP antibody (red) and the SV40 VP2/3 antisera (green). M, molecular mass marker. (D) Immunofluorescence labeling of HeLa cells at 1 dpt with the
SV40 VP4-eGFP expression plasmid, using the SV40 VP2/3 antisera (red) and the DNA stain Draq5 (blue). VP4-eGFP is shown in green. Images were acquired
by confocal microscopy with a 40 objective and a 2 zoom. (E) Western blot of nuclear and cytoplasmic cell fractions of mock-infected and BKPyV-infected
RPTECs harvested at 3 dpi. The membrane was probed with the SV40 VP2/3 antisera. The empty arrowhead indicates a band with the expected size of BKPyV
VP4, and the asterisk indicates a nonspecific band in the mock-infected nuclear fraction. Nuc, nuclear fraction; Cyt, cytoplasmic fraction.
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antibodies were anti-mouse conjugated with Alexa Fluor 568 and anti-
rabbit conjugated with Alexa Fluor 488 or with Alexa Fluor 568 (1:500;
Molecular Probes). Nuclear DNA was labeled with Draq5 (1:1,000; Bio-
status). Images were captured and processed using a Nikon TE2000 mi-
croscope and NIS Elements basic research software, version 4 (Nikon
Corporation), or a Zeiss LSM 780 confocal microscope and ZEN 2 soft-
ware.
Quantification of virus protein-expressing cells. To quantify the
number of VP1-, LTag-, and agnoprotein-expressing cells in immuno-
fluorescently stained cells, the object count feature in NIS Elements soft-
ware was used. Each experiment was done in duplicate wells, and for each
well 5 images were acquired using a 10 objective. For each well, approx-
imately 3,000 to 5,000 Draq5-positive cells were analyzed for virus protein
expression, except for infection with BKPyV WW, where all agnoprotein-
expressing cells were counted.
Quantification of extracellular encapsidated BKPyV and SV40
DNA. Encapsidated extracellular BKPyV and SV40 DNA was quantified
by quantitative PCR (qPCR) of DNase I-treated supernatants using prim-
ers and probes targeting the BKPyV and SV40 LTag gene, respectively (26,
27). The DNase I treatment was performed directly on the supernatants
using the Turbo DNA-free kit (AM1907; Thermo Fisher Scientific) ac-
cording to the manufacturer’s instructions. After DNase I removal, the
supernatants were diluted in molecular-grade water (1:100; Lonza) and
boiled for 5 min before 5 l was used as a template for a 25-l qPCR
mixture. Each sample was analyzed in triplicate.
Virus pelleting. Supernatants from BKPyV-transfected RPTECs or
SV40-transfected CV-1 cells were collected 2 dpt, clarified by low-speed
centrifugation at 10,000  g for 30 min at 4°C, and then ultracentrifuged
in Beckmann ultraclear tubes in an SW 50.1 rotor at 30,000 rpm for 1 h at
4°C. The supernatant was removed and the pellet dissolved in 100 l 10
mM Tris-HCl, 1 mM CaCl2, pH 7.4, and then subjected to protein gel
electrophoresis and Western blotting.
Protein gel electrophoresis and Western blotting. Cells were lysed in
radioimmunoprecipitation assay (RIPA) buffer (21) with protease inhib-
itor (cOmplete, mini, EDTA-free; Roche) or fractionated into nuclear and
cytoplasmic fractions using a nuclear extract kit (40010; Active Motif) at
the indicated time points. When required, total protein concentration was
measured using the EZQ protein quantitation kit (Thermo Fisher Scien-
tific) according to the manufacturer’s instructions. The lysates and frac-
tions were stored at 70°C until separation on a NuPAGE 4 to 12%
Bis-Tris gel (Thermo Fisher Scientific) and blotting onto a polyvinyl di-
fluoride membrane (Thermo Fisher Scientific). The membrane was
blocked with Odyssey blocking buffer (LI-COR Biosciences) and incu-
bated with the following primary antibodies: rabbit polyclonal antiserum
directed against BKPyV VP1 (1:10,000) (25), SV40 VP1 (Ab53977;
1:10,000; Abcam), and SV40 VP2/3 (Ab53983; 1:10,000; Abcam) and
mouse monoclonal antibody directed against glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) (Ab8245; 1:5,000; Abcam) or GFP tag
mouse monoclonal antibody (GF28R; 1:1,000; Médimabs; a kind gift
from Kenneth Bowitz Larsen at the Advanced Microscopy Core Facility,
UiT The Arctic University of Norway). The secondary antibodies were
anti-rabbit and anti-mouse infrared dye-labeled antibodies (IRDye 680LT
goat anti-mouse [1:20,000] and IRDye 800CW goat anti-rabbit [1:
15,000]; LI-COR Biosciences). The Odyssey CLx imaging system (LI-
COR Biosciences) and Image Studio Lite (version 5.2) were used for de-
tection and data acquisition.
Viability assays. The electrical impedance of mock-transfected, SV40
WT-transfected, and VP4-deficient mutant-transfected CV-1 cells was
measured using E plates (E-Plate View; ACEA Biosciences) and the
xCELLigence system (ACEA Biosciences). The background impedance of
the wells was measured after addition of 100 l complete cell medium to
each well. At 6 hpt, 100 l of transfected CV-1 cells was added into the
wells. Each transfection was performed in quadruplicate. Impedance was
measured every 10 min for the first 60 h and then every 30 min up to 120
hpt, when cells were fixed for immunofluorescence staining. Impedance
was expressed as an arbitrary unit called the cell index, and the cell index
for all wells was set to zero at 12 hpt. The impedance of mock-transfected
TABLE 1 Mutated genomes and mutagenesis primers
Original genome (in plasmid form), mutated
genome, and primer designation Mutagenesis primer sequence (5= to 3=) Introduced change in VP2a Start codon targeted
BKPyV Dunlop (pBKV34-2)
VP2M229I
1F GCC CTC AAT AGT TAG ACA AGT AGC TGA AAG aa 229 Putative VP4
1R AAC TAT TGA GGG CCT AAT AGG GGA AAG AT ATG to ATA (Met to Ile)
VP2M229A
2F GCC CTC AGC CGT TAG ACA AGT AGC TGA AAG aa 229 Putative VP4
2R AAC GGC TGA GGG CCT AAT AGG GGA AAG AT ATG to GCC (Met to Ala)
VP2
3F AGG TTC ATA GGT GCT GCT CTA GCA C aa 1 VP2
3R GCA GCA CCT ATG AAC CTG GAA ATA C ATG to ATA (Met to Ile)
VP3
4F GGC ATA GCT TTG GAA TTG TTT AAC CC aa 120 VP3
4R AAA GCT ATG CCT GAT TGC TGA TAG AG ATG to ATA (Met to Ile)
BKPyV WW (pBKV WWT)
WW VP2M229I
1F GCC CTC AAT AGT TAG ACA AGT AGC TGA AAG aa 229 Putative VP4
1R AAC TAT TGA GGG CCT AAT AGG GGA AAG AT ATG to ATA (Met to Ile)
SV40 776 (pWTSV40)
VP2M228I
1F GCC TAC AAT AGT GAG ACA AGT AGC CAA CAG aa 228 Putative VP4
1R CAC TAT TGT AGG CCT AAT GGG AGA CAA AG ATG to ATA (Met to Ile)
VP2M228A
2F GCC TAC AGC CGT GAG ACA AGT AGC CAA CAG aa 228 Putative VP4
2R CAC GGC TGT AGG CCT AAT GGG AGA CAA AG ATG to ATA (Met to Ile)
a aa, amino acid.
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cells was set as a baseline, and the impedance of the other cells was nor-
malized to this. One representative experiment is shown.
Time-lapse microscopy. For continuous microscopic monitoring of
mock-, SV40 WT-, and VP4-deficient mutant-infected CV-1 cells, a
Nikon Biostation (Nikon Corporation) was used. Cells were seeded at
60,000 cells/well in Hi-Q4 culture dishes (Ibidi) in 500 l DMEM with 5%
FBS and a 1:1,000 dilution of the green cyanine dye from the CellTox
green cytotoxicity assay (Promega). Pictures were taken at 5 points in each
well every 15 min from 6 h postinfection (hpi).
Immunoprecipitation. Immunoprecipitation was performed using
SV40 VP2/3 antisera (Ab53983; Abcam) and capturing using protein A
magnetic Sepharose (GE Healthcare). For each immunoprecipitation,
nuclear extracts were harvested at 3 to 6 days postinfection (dpi) from
SV40-infected CV-1 cells grown to confluence on an area of approxi-
mately 87.5 cm2. In short, 10 l of the SV40 antisera mixed with 50 l
nuclear extracts diluted in 250 l Tris-buffered saline (TBS; 50 mM Tris,
150 mM NaCl, pH 7.5) was incubated for 16 h at 4°C with slow end-over-
end mixing. The antibody-antigen complex was captured by the addition
of 20 l protein A magnetic Sepharose followed by incubation for 2 h at
room temperature with slow end-over-end mixing. The Sepharose was
then washed thrice with 500 l TBS. The antibody-antigen complex was
eluted in LDS sample buffer (Thermo Fisher Scientific) containing sample
reducing agent (Thermo Fisher Scientific) by heating to 70°C for 10 min
and was separated on an SDS-PAGE gel.
Dimethyl labeling of proteins. Dimethyl labeling of free N-terminal
ends and lysine residues of proteins in nuclear extracts from SV40-in-
fected CV-1 cells was performed as previously described (28). In brief,
freshly isolated nuclear extracts were incubated for 2 h at 37°C with gentle
agitation in a labeling buffer consisting of 20 mM formaldehyde, 40 mM
sodium cyanoborohydride, and 200 mM HEPES at pH 8.0. The excess
formaldehyde was quenched by addition of glycine to a final concentra-
tion of 60 mM, followed by incubation for 10 min at room temperature.
The samples were then treated with 130 mM hydroxylamine hydrochlo-
ride for 15 min at room temperature before adding LDS sample buffer and
subsequent SDS-PAGE gel separation.
MS. Analysis using liquid chromatography-tandem mass spectrome-
try (LC-MS/MS) was performed at the Tromsø University Proteomics
Platform from gel slices of Coomassie-stained (SimplyBlue SafeStain;
Thermo Fisher Scientific) SDS-PAGE gels. Gel slices were subjected to
in-gel reduction, alkylation, and protease digestion with 6 ng/l trypsin
(V5111; Promega) or 6 ng/l chymotrypsin (V1062; Promega) (29).
OMIX C18 tips (Varian, Inc., Palo Alto, CA, USA) were used for sample
cleanup and concentration. Peptide mixtures containing 0.1% formic
acid were loaded onto a Thermo Fisher Scientific EASY-nLC 1000 system
and EASY-spray column (C18; 2 m; 100 Å; 50 m; 50 cm). Peptides were
fractionated using a 2 to 100% acetonitrile gradient in 0.1% formic acid
over 50 min at a flow rate of 200 nl/min. The separated peptides were
analyzed using a Thermo Scientific Q-Exactive mass spectrometer.
To search for N-terminal VP4 peptides, an inclusion list was used. This
list contained 2 and 3 m/z for the dimethyl-labeled (28 amu), chy-
motrypsin-derived N-terminal peptide (MVRQVANREGLQISF) with
and without methionine. The retention time determined for the positive
control (1 min) was included in the inclusion list. When idle, data were
collected in data-dependent mode using a Top10 method. The raw data
were processed using PEAKS Studio 7 software (v. 7.0; Bioinformatics
Solutions, Canada). Fragmentation spectra were searched in PEAKS
against a combined Chlorocebus and SV40 proteome.
RESULTS
BKPyV-infected RPTECs contain a protein of mass similar to
that of SV40 VP4. In the original SV40 VP4 report, the putative
13.9-kDa protein was detected by Western blotting of nuclear ex-
tracts from SV40-infected BS-C-1 cells using a polyclonal antise-
rum directed against SV40 VP2/3 (9). Similar to SV40 VP4, the
potential BKPyV VP4 protein has a C-terminal NLS (Fig. 1A) and
would also be expected to localize to the nucleus. We first inves-
tigated if a polyclonal SV40 VP2/3 antiserum raised against the
full-length SV40 VP3 protein but previously found to recognize
BKPyV VP2 and VP3 (S. Henriksen and C. H. Rinaldo, unpub-
lished observations) would recognize a recombinant BKPyV VP4
protein with an N-terminal eGFP tag, here denoted eGFP-VP4.
The eGFP-VP4 expression vector was transfected into RPTECs. As
controls, the same expression vector encoding eGFP-VP3, eGFP
alone, or eGFP-VP1 was used. At 24 hpt, cells were fixed and
immunofluorescence staining with the SV40 VP2/3 antiserum or
with BKPyV VP1 antiserum was performed. Confocal microscopy
confirmed that the eGFP-VP4 proteins were localized in the nu-
cleus and verified that they could be recognized by the SV40 VP2/3
antiserum (Fig. 1B). Interestingly, in cells with weak eGFP-VP4
signal, the eGFP-VP4 proteins formed large nuclear inclusions
that were also labeled by the SV40 VP2/3 antiserum (Fig. 1B, left),
while in cells with a stronger eGFP-VP4 signal, the immunostain-
ing was mainly restricted to the nuclear rim, and the inclusions
were smaller and colocalized with the speckled DNA staining (Fig.
1B, right). The DNA staining pattern suggests DNA fragmenta-
tion in cells with high eGFP-VP4 expression. In the control trans-
fections, eGFP-VP3 and eGFP-VP1 localized to the nucleus while
eGFP alone was present in both the nucleus and the cytoplasm
(Fig. 1B). Of note, VP1 contains a different NLS than VP2/3/4. In
the control transfections, no nuclear inclusion bodies or speckled
DNA staining was seen, and in contrast to the eGFP-VP4-express-
ing cells, eGFP-VP3- and eGFP-VP1-expressing cells demon-
strated a high degree of colocalization of the immunostaining and
the eGFP signal.
To confirm that the SV40 VP2/3 antiserum would also recog-
nize denatured BKPyV VP4, we performed SDS-PAGE followed
by Western blotting of cell lysates from CV-1 cells transfected with
the eGFP-VP4 expression vector or expression vectors encoding
eGFP-VP3, eGFP-VP1, or eGFP alone. The Western blot, labeled
with a monoclonal GFP antibody (red) and the SV40 VP2/3 anti-
serum (green), demonstrated bands with the expected molecular
mass of the recombinant proteins (eGFP-VP4, 42 kDa; eGFP-
VP3, 55 kDa; eGFP-VP1, 68 kDa; and eGFP, 28 kDa) (Fig.
1C). Interestingly, in contrast to the eGFP-VP1 lysate, both the
eGFP-VP4 and eGFP-VP3 lysate gave rise to additional bands that
migrated faster than expected and were labeled with both GFP and
SV40 VP2/3 antisera, indicating that the C-terminal part of the
recombinant proteins was prone to degradation or proteolysis.
Several attempts on expressing and detecting untagged BKPyV
VP4 or BKPyV VP4 with a small C-terminal tag, V5-tag, were
unsuccessful. However, when the codons of the SV40 VP4 gene
were optimized to resemble human codon usage, we were able to
produce VP4 with a C-terminal eGFP tag, VP4-eGFP, by transfec-
tion of HeLa cells. VP4-eGFP was mainly localized to the nucleus,
but some cytoplasmic staining also was seen (Fig. 1D), possibly
due to degradation and proteolysis (results not shown).
Together these results suggest that BKPyV VP4, if expressed,
would localize to the nucleus and could be detected by the SV40
VP2/3 antiserum.
We next wanted to investigate the potential expression of
BKPyV VP4 during infection of RPTECs, the natural host cells
for BKPyV during latency and disease. RPTECs were infected with
BKPyV Dunlop and at 72 hpi, corresponding to one complete
replication cycle (30, 31), cells were harvested and separated into
cytoplasmic and nuclear fractions before SDS-PAGE and Western
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blotting with the SV40 VP2/3 antiserum was performed. Cyto-
plasmic and nuclear fractions from mock-infected cells were used
as controls. As expected, a strong expression of proteins with the
predicted size of VP2 and VP3 was observed only in nuclear ex-
tracts from BKPyV-infected cells (Fig. 1E). In addition, a slightly
faster migrating band was observed below VP2 and VP3. Based on
the results shown in Fig. 1C, this is probably protolysed VP2 and
VP3, respectively. Of note, a weak band with the predicted size of
VP4 was seen, suggesting that BKPyV expresses VP4. Similar to
the original SV40 VP4 report (9), we also detected a faint band
with a lower molecular mass which could correspond to a protein
made from one of the two downstream ORFs (Fig. 1A). A weak
band between 10 and 15 kDa was also noted in mock-infected
cells. Moreover, for both mock-infected and BKPyV-infected
cells, several bands with molecular masses higher than 37 kDa
were observed, possibly due to unspecific binding of the SV40
VP2/VP3 antiserum.
We conclude that BKPyV might express a VP4 protein and that
this probably is located in the nucleus. A novel truncated form of
VP4, denoted VP5 or VP6, may be expressed as well.
BKPyV strain Dunlop does not require the nonstructural
protein VP4 or minor capsid proteins VP2/VP3 for progeny re-
lease, but VP2-, VP3-, and VP4-deficient mutants show reduced
infectivity compared to the WT strain. In the original VP4 report
(9), a VP4-defective mutant, termed VP2M228I, was created by
changing the start codon from ATG (methionine) to ATA (isoleu-
cine), thereby unavoidably introducing one point mutation into
both VP2 and VP3. In order to study the function of the putative
BKPyV VP4 protein, we used site-directed mutagenesis to create a
homologous VP4-deficient BKPyV mutant, VP2M229I. To re-
duce the possibility of revertants and to explore the tolerance of
mutations for VP2/3 functions, we generated a second mutant,
VP2M229A, by changing the start codon to GCC (alanine). As
controls, we also made mutants with start codon substitutions
(methionine to isoleucine) in VP2 (VP2), in VP3 (VP3), and in
both VP2 and VP3 (VP2/VP3).
In order to test protein expression directed from the different
recombinant viruses, we transfected equal amounts of the mu-
tated genomes into RPTECs and harvested cell lysates for Western
blot analysis at 2 days posttransfection (dpt) (Fig. 2A). SDS-PAGE
followed by Western blotting with the SV40 VP2/3 antiserum in
combination with the BKPyV VP1 antiserum demonstrated that
cells transfected with the VP4-deficient mutants produced VP2
and VP3. The VP2-deficient mutant and the VP3-deficient mu-
tant only produced VP3 or VP2, respectively, while no minor cap-
sid proteins were detected in cells transfected with the VP2/3-
deficient mutant. Moreover, all mutants produced VP1 at levels
comparable to the WT virus.
In order to investigate the release of viral progeny after about
one replication cycle, we again transfected RPTECs with equal
amounts of the WT and the mutated genomes and harvested the
supernatants at 3 dpt for quantification of encapsidated viral ge-
nomes (i.e., DNase I-protected BKPyV DNA) by qPCR. The
DNase I digestion step reduced the amount of nonencapsidated
viral DNA originating from the transfection (input at 1 dpt) to
about 106 genomic equivalents (GEq)/ml (Fig. 2B). The results
showed a 	2-log increase in encapsidated BKPyV DNA in super-
natants from cells transfected with BKPyV WT 3 dpt (Fig. 2B).
Surprisingly, given the suspected role of VP4 in viral release, both
VP4-deficient mutants were released at a similar level (Fig. 2B),
suggesting that BKPyV does not require VP4 for viral progeny
release. Interestingly, a similar release was also found for virions
without VP2 or VP3 or without both VP2 and VP3 (Fig. 2B). To
ensure that this unaffected release was not due to the host cells
chosen, the transfections were repeated in Vero cells. However,
the results were similar to what we found in RPTECs (results not
shown). To confirm that cells transfected with the different mu-
tants actually released virions, Vero cells were transfected with the
same constructs and supernatants harvested 2 dpt. Virions were
pelleted by ultracentrifugation, and a portion of this was analyzed
by SDS-PAGE and Western blotting, using the same combination
of the VP2/3 and VP1 antisera as before. Based on the VP1 band,
the result confirmed a similar amount of extracellular virus for all
mutants (Fig. 2C). In addition, the results confirmed the absence
and presence of VP2 and VP3 in the mutants.
Since we did not find that the absence of VP4 affected BKPyV
release when the entry events were bypassed by DNA transfection,
we next investigated if the early events in the replication cycle were
affected by the lack of VP4. Supernatants harvested from RPTECs
3 dpt were used to infect new RPTECs, and immunofluorescent
staining with a combination of antisera directed against BKPyV
agnoprotein and a monoclonal antibody directed against LTag
was performed at 3 dpi. Immunofluorescence microscopy re-
vealed that 27% and 11% of cells infected with the WT virus su-
pernatant expressed LTag and agno protein, respectively (Fig.
2D). Compared to WT virus, both of the VP4-deficient mutants
displayed reduced infectivity. Interestingly, the VP2M229A mu-
tation was better tolerated by the virus, giving only a 65% overall
reduction, compared with the 90% reduction of the VP2M229I
mutation. If the reduced infectivity was caused by the lack of VP4,
we would have expected a similar infectivity of the two VP4-defi-
cient mutants. Since this was not the case, the results suggest that
at least part of the observed reduction in infectivity was due to the
simultaneous introduction of one amino acid change in the VP2
and/or VP3 sequence that was unavoidably created during VP4
start codon mutation.
The importance of the minor capsid proteins in infection was
further emphasized by the fact that that mutants deficient in either
VP2 or VP3 or both VP2 and VP3 were almost noninfectious,
causing a more than 99% reduction of LTag and agno protein
expressing cells compared to the WT strain (Fig. 2D).
We conclude that VP4 has no measurable role in BKPyV re-
lease in cell culture. Not surprisingly, the presumed late and non-
structural VP4 is not required for the early steps of the viral repli-
cation cycle. However, what seems clear is that amino acid 229 in
VP2 and/or amino acid 110 in VP3, both overlapping the VP4
start codon, play important roles in the early steps of the BKPyV
replication cycle.
The archetype strain of BKPyV, WW, does not require VP4
for efficient progeny release, but a mutation of VP2 amino acid
229 and/or VP3 amino acid 110 causes reduced infectivity com-
pared to the WT strain. In the above-described experiments, we
used the BKPyV strain Dunlop, which has a high replication ca-
pacity in both primary human RPTECs and in various cell lines. In
contrast to this, the BKPyV archetype strain WW, usually found in
urine of healthy individuals, has a low replication capacity both
in vivo and in cell culture (10, 11). Although the low replication
capacity is mainly caused by a low level of early gene expression
and DNA replication, the mechanism for virion release might also
differ. We therefore investigated if the WW strain required the
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FIG 2 BKPyV VP4 is not required for viral progeny release, but VP4 start codon substitution affects infectivity. (A) Western blot of RPTEC cell lysates harvested
at 2 dpt with the indicated BKPyV genomes. The membrane was probed with rabbit BKPyV VP1 antisera (green) and rabbit SV40 VP2/3 antisera (green). Mouse
GAPDH antibody was used as a loading control (red). The asterisk indicates binding to a nonspecific cellular protein by the VP1 or VP2/3 antisera. M, molecular
mass marker. (B) BKPyV load in DNase I-treated supernatants from RPTECs at 1 and 3 dpt, determined by real-time quantitative PCR and presented as GEq/ml.
The figure represents data from three independent experiments, each performed in duplicate wells, and the error bars indicate the standard deviations. (C)
Western blot of capsid proteins pelleted by ultracentrifugation from Vero cell supernatants harvested 3 dpt. A volume corresponding to 400 l supernatant was
loaded on the gel. The membrane was probed with rabbit BKPyV VP1 antisera (upper) and rabbit SV40 VP2/3 antisera (lower). The signal intensity in the lower
panel was increased for better visualization of the VP2 and VP3 proteins. (D) Immunofluorescence staining of RPTECs at 3 dpi with the indicated BKPyV variants
at similar BKPyV load (approximately 8 log10 GEq/ml), using the rabbit agno antisera (green) and the mouse monoclonal LTag antibody (Ab-2; red). Repre-
sentative images of the immunofluorescence staining are shown in the upper panel, and quantification in relation to the WT infection is displayed in the graph
in the lower panel. Each experiment was done in duplicate and repeated twice. Approximately 3,000 to 5,000 Draq5-positive cells per well were analyzed for virus
protein expression.
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putative VP4 protein for viral progeny release. Using the same
experimental approach as that for the Dunlop strain, we created a
WW strain with a VP4 start codon mutation, WW VP2M229I,
and transfected both the wild-type WW strain (WW WT) and the
mutant into RPTECs. As expected, qPCR of the DNase I-treated
supernatants 3 dpt confirmed that the infection with WW WT
progressed much slower than that with the Dunlop strain. The
DNA load was about 107 GEq/ml (Fig. 3A), which was about 1 log
less than that for Dunlop (Fig. 2B), but increased to similar levels
by 6 dpt (Fig. 3A). Importantly, the VP4-deficient mutant was
released at a similar level (Fig. 3A). These results suggest that,
similar to BKPyV Dunlop, archetypal BKPyV does not require
VP4 for progeny release.
To investigate the effects of the mutation on early events, super-
natants from 6 dpt were used to infect RPTECs, and this was followed
by immunofluorescent staining at 3 dpi. Although we observed fewer
infected cells in RPTECs inoculated with supernatants from the VP4-
deficient mutant than cells inoculated with WW WT supernatants,
the overall low number of infected cells made it difficult to determine

























































FIG 3 BKPyV VP4 is not required for viral progeny release of the WW strain, but the VP4 start codon substitution M229I affects infectivity. (A) BKPyV load in
DNase I-treated supernatants from RPTECs at 3 and 6 dpt, determined by real-time quantitative PCR and presented as GEq/ml. The figure represents data from
two independent experiments, each performed in duplicate wells, and the error bars indicate the standard deviations. (B) Immunofluorescence staining of COS-7
cells 4 dpi with BKPyV WW WT and BKPyV WW VP2M229I at similar viral loads (approximately 8 log10 GEq/ml) using a BKPyV VP1 antibody (red) and the
agno antisera (green). Representative images of the immunofluorescence staining are shown in the upper panels, and quantification in relation to WT infection
is displayed in the graph in the lower panel. Each experiment was performed twice in duplicate wells. All agno-positive cells present in 0.75-cm2 wells were
counted.
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infected COS-7 cells, a cell line that constitutively produces SV40
LTag. By doing this, we were able to slightly increase the number of
WW WT-infected cells (Fig. 3B). Compared to the WT, the infectiv-
ity of the mutant was 98% reduced (Fig. 3B).
We conclude that VP4 is not required for WW release. Taken
together with our earlier results, these results suggest that the al-
teration of amino acid 229 in VP2 and/or amino acid 110 in VP3,
from methionine to isoleucine, reduces infectivity of BKPyV WW.
SV40 infection in various cell lines does not require VP4 for
efficient progeny release; however, the SV40 VP4-deficient mu-
tant VP2M228I, but not VP2M228A, show reduced infectivity
compared to SV40 WT. Given our surprising results for the
BKPyV VP4-deficient mutants, we decided to apply our methods
using SV40 WT and VP4-deficient mutants both to validate our
methods and repeat essential experiments performed by Daniels
et al. (9). By site-directed mutagenesis of the genome of SV40
strain 776, we recreated the VP4-deficient mutant used in the
original SV40-VP4 paper, SV40 VP2M228I. Due to the observed
differences in infectivity between the two BKPyV VP4-deficient
mutants, we also created SV40 VP2M228A. Due to the diversity in
the biology of different cells (32), we used three different cell lines:
BS-C-1, which was used in the original SV40-VP4 report, CV-1
cells, and Vero cells. Cells were transfected with equal amounts of
WT SV40 or the two VP4-deficient mutants, and supernatants
were harvested at 1, 2, and 4 dpt. In addition, supernatants from
BS-C-1 cells were harvested at 5 dpt, since this time point was
described in the original report as the time with the highest VP4
expression. An SV40-specific qPCR of DNase I-treated superna-
tants revealed that transfection of SV40 WT DNA in BS-C-1 cells
gave an approximately 1-log increase in encapsidated viral ge-
nomes from 1 dpt to 2 dpt, an additional 1-log increase from 2 dpt
to 4 dpt, and only a 0.5-log increase from 4 dpt to 5 dpt (Fig. 4A).
Similarly, as observed for BKPyV VP4-deficient mutants, the
SV40 VP4-deficient mutants were released at the same levels as the
SV40 WT (Fig. 2B and 4A). In addition, when CV-1 cells or Vero
cells were transfected, the SV40 VP4-deficient mutants were re-
leased at levels similar to the SV40 WT (Fig. 4A and data not
shown). Of note, the amount of viral encapsidated genomes re-
leased from CV-1 cells and Vero cells at 2 dpt was approximately 1
log higher than that from BS-C-1 cells, suggesting either a more
efficient transfection or a faster replication cycle than that in BS-
C-1 cells.
The release of virions was also investigated by transfection of
CV-1 cells followed by ultracentrifugation of supernatants har-
vested at 2 dpt, SDS-PAGE, and Western blotting of the pelleted
virions. Based on the VP1, VP2, and VP3 bands, the result again
confirmed a similar amount of released extracellular virus for the
WT and VP4-deficient mutants (Fig. 4B). In agreement with ob-
servations by Daniels et al. (9), VP4 was not detected. We con-
cluded that encapsidated genomes of the WT and the mutants
were released at similar levels from transfected BS-C-1, CV-1, and
Vero cells. Moreover, for BS-C-1 cells the majority of the progeny
was already released at 4 dpt.
The BKPyV VP4-deficient mutants seemed to be inhibited in
one or more early steps in the replication cycle prior to the DNA
replication step (Fig. 2B, C, and D). To investigate if this was also
the case for SV40 VP4-deficient mutants, we examined the infec-
tivity of the SV40 progeny in CV-1 cells. Supernatants harvested
from CV-1 cells at 2 dpt, containing progeny of either SV40 WT or
the VP4-deficient mutants VP2M228A and VP2M228I, were used
to infect new CV-1 cells. At 2 dpi, the cells were fixed and stained
for LTag and VP1. Immunofluorescence microscopy revealed that
infection with supernatants from three independent SV40 WT
transfections resulted in between 14.3 and 25.2% LTag-expressing
cells, i.e., infected cells. The percentage of cells with detectable VP1
staining ranged from 4.5 to 9.4%. Compared to supernatants from
SV40 WT-transfected cells, supernatants from SV40 VP2M228I-
transfected cells were less successful at infecting new CV-1 cells.
The reduction was 43% and 57% for LTag and VP1, respectively
(Fig. 4C). Interestingly, and in accordance with the results from
BKPyV experiments (Fig. 2D), the SV40 VP2M228A mutation
was better tolerated by the virus and resulted in an insignificant
decrease of CV-1 infected cells (Fig. 4C).
We next wanted to investigate the expression of SV40 VP4
during infection of CV-1 cells. CV-1 cells were infected with the
WT or the VP2M228I or VP2M228A mutant. At 72 hpi, the cells
were harvested and separated into cytoplasmic and nuclear frac-
tions before SDS-PAGE and Western blotting with the SV40
VP2/3 antiserum was performed. Cytoplasmic and nuclear frac-
tions from mock-infected cells were used as controls. As expected,
a strong expression of proteins with the predicted size of VP2 and
VP3 was observed in nuclear extracts from WT-infected cells (Fig.
4D). As observed for BKPyV (Fig. 1E), a slightly faster migrating
band was observed below VP2 and VP3. In addition, VP2 and VP3
were found in the cytoplasmic fractions, with some of them pos-
sibly originating from the virus inoculation. The pattern was the
same for VP2M228I and VP2M228A but all bands were weaker for
VP2M228I, supporting the earlier suggested reduced infectivity.
Of note, a weak band between 8 and 15 kDa was seen for both WT
and VP4-deficient mutants but was stronger in cytoplasmic than
in nuclear fractions. Importantly, this band was also observed in
fractions of mock-infected cells. As observed with fractions from
RPTECs (Fig. 1E), several bands with molecular masses greater
than 38 kDa were observed for both mock-infected and SV40-
infected cells, possibly due to unspecific binding of the VP2/3
antiserum.
We conclude that SV40 does not need VP4 for an efficient
release of progeny from BS-C-1 cells, CV-1 cells, or Vero cells. Of
note, this is in disagreement with the conclusions made in the
original SV40 VP4 report. Similar to what we observed for BKPyV,
a methionine-to-isoleucine mutation in VP2 amino acid 228
and/or VP3 amino acid 110 reduces the infectious potential of
SV40; however, for SV40 a methionine-to-alanine mutation is
well tolerated. Western blotting of nuclear and cytoplasmic frac-
tions from SV40-infected cells using the VP2/3 antisera revealed a
band of size similar to that of VP4, but since this band was found
in fractions from VP4-deficient mutants and mock-infected cells,
this is unlikely to be VP4 and seems to be a cellular protein.
SV40 VP4 is not detected upon immunoprecipitation using
SV40 VP2/3 antiserum or directly from nuclear extracts by MS
analysis. As shown in Fig. 4D, we did detected a protein between
8 and 15 kDa in nuclear extract from SV40 WT-infected CV-1 cells
by Western blotting with the SV40 VP2/3 antisera. In order to
possibly detect VP4, we used LC-MS/MS. We first performed im-
munoprecipitation of the nuclear extract using the SV40 VP2/3
antisera. Nuclear extracts from SV40 WT-infected CV-1 cells were
harvested when most of the cells displayed cytopathic effect (3 to 6
dpi), i.e., when expression of the putative very late VP4 protein
presumably would be at its maximum. Western blotting of the
immunoprecipitated proteins showed strong VP3 and VP2 bands
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and some weaker faster-migrating bands about the size of VP4
(Fig. 5A). In Coomassie-stained SDS-PAGE gels, visible bands
below 20 kDa were subjected to in-gel trypsin digestion and LC-
MS/MS. In addition to some cellular proteins (data not shown),
we were able to detect three viral peptides. While two were derived
from VP2 and/or VP3, one of them could be derived from VP4
(Fig. 5B). However, due to the common C terminus of VP2/3/4, it
could also be derived from the two minor capsid proteins. None of
the peptides could originate from the putative VP5.
Two bands corresponding to the size of VP2 were also visible
and were identified by LC-MS/MS as originating from VP2. VP3
was not clearly seen on Coomassie-stained gel, as VP3 comigrates
with the IgG light chains deriving from the antibodies used in the
immunoprecipitation. This experiment was repeated once with
the same result.
Since the minor capsid proteins are known to be hydrophobic
and thus might not be the ideal substrate for trypsin (33), the
experiment was repeated using chymotrypsin instead of trypsin.
Gel pieces from approximately 21 kDa to 6 kDa were excised (Fig.
5C), fragmented, and subjected to LC-MS/MS for identification.
This time, peptides deriving from viral proteins were not detected
in gel pieces below 21 kDa. From the gel piece excised close to 21.5
kDa, three viral peptides were detected, and one of them could
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FIG 4 SV40 VP4 is not required for viral progeny release, but the VP4 start codon substitution affects infectivity. (A) SV40 load in DNase I-treated supernatants
from BS-C-1 cells and CV-1 cells at 1, 2, 4, and 5 dpt, determined by real-time quantitative PCR and presented as GEq/ml. The figure represents data from three
independent experiments (except BS-C-1 cells at 5 dpt and CV-1 cells at 4 dpt, which were performed twice). Each experiment was performed in duplicate wells,
and the error bars indicate the standard deviations. (B) Western blot of capsid proteins pelleted by ultracentrifugation of CV-1 cell supernatants harvested 2 dpt.
A volume corresponding to 400 l supernatant was loaded on the gel. The membrane was probed with SV40 VP1 and VP2/3 antisera. (C) Quantification of
infectivity in CV-1 cells at 2 dpi with SV40 WT and VP4-deficient mutants. CV-1 cells were infected with the indicated SV40 variants at similar viral load
(approximately 10 log10 GEq/ml). Quantification of LTag- and VP1-positive cells in relation to the SV40 WT infection, determined by immunofluorescence
microscopy, is displayed in the graph. Immunofluorescence staining was performed using the SV40 VP1 antisera and the LTag antibody (Pab419), and the
quantification is related to the number of SV40 WT-infected cells. Each experiment was done in duplicate and repeated twice. Approximately 3,000 to 5,000
Draq5-positive cells per well were analyzed for virus protein expression. (D) Western blot of nuclear and cytoplasmic fractions from CV-1 cells that were mock
infected or SV40 infected with the indicated SV40 variants and harvested at 2 dpi. The membrane was probed with SV40 VP2/3 antisera. The empty arrowhead
indicates a band with a size similar to that of the putative VP4 protein. Nuc, nuclear fraction; Cyt, cytoplasmic fraction; M, molecular mass marker.
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likely derived from degraded VP2 or VP3. We again excised the
two bands that corresponded to VP2, and LC-MS/MS was able to
identify 12 peptides deriving from VP2 (Fig. 5C), proving that
chymotrypsin is suitable for fragmentation of VP2/3/4.
Since immunoprecipitation using the SV40 VP2/3 antiserum
gave significant amounts of background and minimal concentrat-
ing effect, we attempted to detect SV40 VP4 directly from nuclear
extracts of SV40-infected CV-1 cells by LC-MS/MS. By combining
N-terminal dimethyl labeling at the protein level with LC-MS/MS,
it is possible to identify the N-terminal part of a protein. There-
fore, to be able to separate the N terminus of VP4 from VP2 or VP3
peptides, we performed dimethyl labeling of the N terminus in
nuclear extracts from SV40-infected CV-1 cells. If VP4 is present
in the sample, this labeling will give a VP4-specific peptide distin-
guishable from VP2/3-derived peptides. To create a positive con-
trol containing the dimethyl-labeled N-terminal VP4 peptide, we
first transfected the SV40 VP4-eGFP expression vector into CV-1
cells (Fig. 1D) and subjected the nuclear extract at 1 dpt to di-
methyl labeling. The fusion protein was used to determine the LC
retention time of the N-terminal dimethyl-labeled chymotryptic
peptide of VP4. In this sample, we identified two chymotryptic














































































FIG 5 SV40 VP4 is not detected upon immunoprecipitation (IP) using SV40 VP2/3 antiserum. (A) Western blot (WB) of immunoprecipitated proteins from
nuclear extracts of SV40-infected CV-1 cells at 6 dpi. Immunoprecipitation was performed using the SV40 VP2/3 antisera. The membrane was probed with SV40
VP2/3 antisera. M, molecular mass marker. (B) Schematic presentation of the location in VP2 of the peptides identified by LC-MS/MS from visible bands below
20 kDa excised from a Coomassie-stained SDS-PAGE gel after immunoprecipitation. Note that the SV40 VP5 ORF is similar to the BKPyV VP6 ORF, as shown
in Fig. 1A. (C) Coomassie-stained SDS-PAGE gel of immunoprecipitated proteins from nuclear extracts of SV40-infected CV-1 cells at 6 dpi. The location of the
excised bands and the sequence of VP2/3/4 peptides detected in these bands are listed. The initial methionine residues for both VP3 and VP4 are highlighted in
red. The gel pieces were fragmented in gel by chymotrypsin. ND, not detected; M, molecular mass marker.
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both with dimethylated N-terminal valine. As evidenced by the
missing N-terminal methionine and dimethylation at valine, the
N-terminal methionine is removed by the host methionine ami-
nopeptidase (34). In addition, other internal chymotryptic pep-
tides were identified, leading to a 56% sequence coverage of the
VP4 protein in the positive control.
In the sample from infected cells, two peptides that could orig-
inate from VP2, VP3, or VP4 were found, as well as one peptide
originating from VP2 or VP3. However, careful examination of
the raw data showed no trace of the possible N-terminal peptides
of VP4. In addition, the major capsid protein VP1 was identified
with a total of 7 chymotryptic peptides.
We conclude that there is no decisive evidence of VP4 in nu-
clear extracts from SV40-infected CV-1 cells upon immunopre-
cipitation with an SV40 VP3 antisera or by an unbiased approach
using N-terminal dimethyl labeling.
The VP4-deficient mutant SV40 VP2M228A, but not SV40
VP2M228I, displays lytic properties similar to those of the SV40
WT strain. In the original VP4 report (9), trypan blue staining of
infected BS-C-1 cells was used to demonstrate a 2-day delay in cell
lysis caused by the VP4-deficient mutant SV40 VP2M228I (5 dpi)
compared to SV40 WT (3 dpi).
Given the observed differences in infectivity between the two
SV40 VP4-deficient mutants (Fig. 4C), we decided to compare the
effect of the SV40 WT and VP4-deficient mutants on host cell
viability in real time by the use of the xCELLigence system. This
system utilizes electrode sensor arrays in the bottom of each well,
emitting noninvasive electric signals, and measures changes in
electrical impedance displayed as an arbitrary unit termed the cell
index. Electrical impedance and, consequently, cell index, in-
creases with increasing cell number, size, and attachment and thus
gives an indication of the overall cell viability.
To ensure equal amounts of the different viruses, we initiated
infection of CV-1 cells by DNA transfection. The transfection ef-
ficiency was low at approximately 10%. CV-1 cells were selected as
the replication cycle seems quicker than that in BS-C-1 cells (Fig.
4A), allowing at least two replication cycles of SV40 WT to occur
during the 5-day-long experiment. At about 6 hpt, cells were
trypsinized and seeded into wells in the E-plate, and the 120 h of
monitoring started. The cells transfected with an empty plasmid
vector (mock) were proliferating throughout the experiment, giv-
ing a steady increase in cell index; therefore, the cell indexes of cells
transfected with SV40 WT, VP2M228I, or VP2M228A were nor-
malized to the cell index of mock-transfected cells (Fig. 6A). From
about 48 hpt, a decline in the cell index of wells with virus-trans-
fected cells was observed. Interestingly, the decline was equal for
all SV40 variants and coincided in time with the approximately
3-log increase of released DNase I-protected virus DNA observed
in Fig. 4A, suggesting that the decline was caused by lytic progeny
release from the virus-transfected cells. Shortly before 90 hpt, the
cell index of the wells with WT virus started to decline steeply and,
with a few hours’ delay, was followed by a decline in the cell index
of the VP2M228A mutant. According to the experiment depicted
in Fig. 4A, at 96 hpt, the virus DNA load is further increased by 1
log, which suggests that the latter decline was caused by lytic re-
lease of virions from cells infected by progeny virus during the
experiment. By the end of the experiment at 120 hpt, the cell index
in wells with the WT and the VP2M228A mutant was clearly dif-
ferent from those of the wells with mock-transfected cells and
wells with the VP2M228I mutant. While both the WT virus and
the VP2M228A mutant caused an 6-U decline in cell index, the
VP2M228I mutant caused only a 2-U decline compared to
mock-transfected cells. The remaining cells were fixed and stained
for LTag (red), VP1 (green), and DNA (blue) (Fig. 6A). As indi-
cated by the decline in cell index, the number of cells in wells
transfected with the WT and VP2M228A mutant was severely re-
duced, supporting virus-induced lytic release. The number of cells
in wells transfected with VP2M228I was also reduced compared to
wells with mock-transfected cells but to a lesser degree, again in
agreement with the cell index curve (Fig. 6A).
For a visual investigation of the lytic properties of the SV40 WT
and the VP4-deficient mutants over time, real-time microscopy of
CV-1-infected cells in the presence of a DNA stain staining only
dead cells was used. In short, CV-1 cells were infected by CV-1
supernatants harvested at 2 dpt, the green cyanine dye was added,
and photographs were taken every 15 min up to 5 dpi. While cells
infected with the WT or the VP2M228A mutant started to die
from 2 dpi, initial cell death in VP2M228I-infected cells was de-
layed by about 1 day (Fig. 6B; also see Movies S1 to S4 in the
supplemental material). At the end of the experiment 5 dpi, im-
munofluorescence staining was performed. VP1 staining revealed
fewer infected cells, and the phase contrast showed a more con-
fluent cell layer for the VP2M228I-infected cells than for WT- and
VP2M228A-infected cells (Fig. 6C).
We conclude that the virus-induced cell death is not dependent
on VP4. Since the progeny mainly from WT- and VP2M228A-
transfected cells seemed to efficiently initiate a lytic infection of
new cells, methionine in position 228 in VP2 and/or position 110
in VP3 seems to be required for optimal viral fitness.
DISCUSSION
Several steps in the replication cycle of polyomaviruses remain
enigmatic despite several decades of investigation. Among the
least-studied steps is viral egress. As for other nonenveloped vi-
ruses, viral egress earlier was thought to exclusively occur passively
by host cell lysis. A decade ago, however, this concept was chal-
lenged in the case of polyomaviruses, as it was reported that the
newly discovered SV40 VP4, possibly in collaboration with the
minor capsid proteins VP2/3, act as a viroporin triggering host cell
lysis in a more active and timely manner. Here, we show that VP4
is not required for release of BKPyV from RPTECs. More surpris-
ingly, and contradicting the previous report, VP4 is not required
for efficient release of SV40 from various permissive cell types,
including BS-C-1. Despite several attempts, we were not able to
detect SV40 VP4 in SV40-infected cells by mass spectroscopy.
Due to the reported finding of VP4 in SV40, we sought to
investigate if we could detect VP4 in BKPyV-infected RPTECs.
The antiserum raised against SV40 VP3 was found to recognize
recombinant BKPyV eGFP-VP4 fusion proteins (Fig. 1B and C),
and we were able to detect a couple of faint bands between 10 and
15 kDa when this antibody was used for Western blot analysis of
nuclear extracts from BKPyV-infected RPTECs (Fig. 1E). How-
ever, it is apparent that the SV40 VP2/3 antiserum recognizes a
range of cellular proteins, including a faint band between 8 and 15
kDa in the mock-infected RPTECs as well as in CV-1 cells (Fig.
4D), raising the possibility that a cellular protein could have been
misidentified as VP4 in the original paper.
Surprisingly, transfection experiments using BKPyV and SV40
VP4-deficient mutants, as well as BKPyV deficient in one or both
minor capsid proteins, showed that all mutants were capable of
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C WT VP2M228I VP2M228A Mock
FIG 6 SV40 VP2M228I shows a delayed and reduced host cell lysis compared to WT SV40. (A) Electrical impedance in SV40-transfected CV-1 monolayers was
measured using the xCELLigence system from 6 to 120 hpt. The cell index was normalized to the cell index of mock-transfected cells. The experiment was
repeated 2 times, and a representative experiment where the cell index of 4 parallel wells was measured and shown as means with standard deviations is presented.
At the end of this experiment, immunofluorescence staining was performed using the SV40 VP1 antisera (green), an LTag antibody (Pab419; red), and the DNA
stain Draq5 (blue). (B) Time-lapse microscopy was used to monitor SV40-infected CV-1 monolayers from 6 hpi until 120 hpi (5 dpi). A green cyanine dye
staining the DNA of dead cells green was added directly after infection. Photos were taken every 15 min, and selected time points (6 hpi, 2 dpi, 3 dpi, and 5 dpi)
are shown. (C) Immunofluorescence staining of SV40-infected CV-1 cells at the end of the time-lapse experiment described for panel B, using the SV40 VP1
antisera (red). A Nikon Biostation was used to take immunofluorescence and phase contrast images, and merged images are shown.
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releasing virions at levels similar to that of the WT strains (Fig. 2B
and C and 4A and B). However, the infectivity of the BKPyV
mutants deficient for either VP2, VP3, VP4, or both VP2 and VP3
was strongly reduced. Similar results were found for the SV40
VP4-deficient mutant VP2M228I, while the VP2M228A mutant
was still infectious (Fig. 2D and 4C).
The fact that the VP4-deficient mutants of both BKPyV and
SV40 all were able to produce and release progeny viruses upon
DNA transfection of several relevant susceptible cells rules out
that VP4 has a role in viral progeny release, at least in cell culture.
In addition, the lack of VP4 in the viral particle (Fig. 4B) excludes
a role in viral entry. It is obvious, however, that the infectivity of
the VP4-deficient mutants is reduced. The mutation of one amino
acid in BKPyV VP2 (amino acid 229) and/or BKPyV VP3 (amino
acid 110), and likewise one amino acid in SV40 VP2 (amino acid
228) and/or SV40 VP3 (amino acid 110), seems to negatively affect
the viral replication cycle at a stage prior to viral DNA replication,
as the effect is not noticed upon DNA transfection. Alteration of
methionine to isoleucine is less tolerated than alteration to ala-
nine, and the noticed difference in infectivity between the differ-
ent mutants supports that the effect is due to alteration in VP2 or
VP3 rather than the loss of the VP4 ORF. This methionine is a part
of a conserved motif (MVRQVA) in the VP2/3 proteins found in
about 20% of human and nonhuman primate polyomaviruses
(35, 36).
When Daniels et al. (9) infected BS-C-1 cells with SV40 WT
and the VP4-deficient SV40 VP2M228I mutant, they observed
a significant decrease in the infectivity and host cell lysis for the
latter and attributed this to the mutant’s defect in lytic release.
Also in a recent paper from an independent group investigating
SV40 virus protein involvement in vacuolization, a deficient
release of infectious virus particles for the SV40 VP2M228I
mutant was concluded (37). In our opinion, both of these stud-
ies used inadequate methods to characterize the release of the
mutants. We applied methods involving transfection, which
bypasses the viral entry stage, quantitative PCR of DNase I
protected viral DNA in supernatants, and Western blotting of
released virus, and this revealed similar levels of extracellular
viral DNA and proteins for all mutants. However, when infect-
ing naive cells with similar titers of virus, as quantified by
qPCR, the infectivity of VP4-deficient mutants was clearly re-
duced. This indicates a high ratio of viral DNA to infectious
particle compared to that for the WT. Hence, we suggest that
the reduction in the infectivity of the VP4-deficient mutant
seen by us, Daniels et al. (9), and Luo et al. (37) is indeed due to
a defect in entry events and not to release of the mutants.
Interestingly, the VP4-deficient SV40 mutant VP2M228I
was recognized by Tange et al. (38) to be identical to that of the
SV40 temperature-sensitive D-type mutant, tsD222. This class
of temperature-sensitive mutants exhibit, at the restrictive
temperature of 40°C, an apparent defect in the uncoating pro-
cess, as shown by a failure to initiate viral replication (39). The
viral DNA of these mutants were, however, able to initiate in-
fection similar to that of the WT upon DNA transfection (40,
41). Tange and coworkers were not able to reproduce the West-
ern blot results from the original VP4 report even when using
SV40 VP2/3 antibodies from the same source. Apparently, they
frequently detected proteins of approximately 25, 18, 16, and
12 kDa deriving from VP2/3. By doing complementation ex-
periments, Tange and colleagues concluded that the growth
defect of the tsD222 mutant was not due to the lack of VP4-
ORF (38) and thus support our conclusions.
Mutating the start codons of the BKPyV minor capsid proteins
alone or together reduced infectivity by over 99% compared to the
WT. As far as we know, this is the first time this has been demon-
strated for BKPyV, but it is in agreement with experiments done
with BKPyV pseudoviruses or mouse polyomavirus, SV40, and
JCPyV mutants deficient in either VP2 or VP3 or both VP2 and
VP3 (42–46). Based on our results, we conclude that VP2 is crucial
in early events of a BKPyV infection in RPTECs. The same seems
to be true for VP3, but there is a possibility that the observed
difference for the VP3-deficient mutant is an effect of the muta-
tion introduced in amino acid position 120 in VP2. To investigate
this, one could make other VP3-deficient mutants by replacing
this methionine in VP2 with less bulky amino acids. Although the
entry of BKPyV and SV40 into host cells is not fully understood,
SV40 VP2 in particular seems to play essential roles in the trans-
port of the partly dissembled particles from the endoplasmic re-
ticulum (ER) to the cytosol (47–49), while both VP2 and VP3 for
both SV40 and BKPyV are important for the nuclear import of the
viral genomes (50, 51). So far, we do not know which of these steps
are disrupted during infection with our mutants.
Attempts to conclusively identify VP4 in nuclear extracts from
SV40-infected CV-1 cells using LC-MS/MS failed. By immuno-
precipitation using the SV40 VP2/3 antiserum, we were able to
detect peptides that could originate from VP2, VP3, or VP4, but
detection of VP2 and VP3 peptides in samples that migrated below
20 kDa on SDS-PAGE indicated that VP2 and VP3 are prone to
degradation or proteolysis (Fig. 1C). This has also been observed
by Tange et al. (38). Similar results were obtained when LC-
MS/MS was performed directly on nuclear extracts from SV40-
infected cells CV-1 following N-terminal dimethyl labeling.
Based on our results, we believe that BKPyV and SV40 progeny
is released from host cells by a mechanism not depending on a VP4
viroporin. While Movies S1 to 4 in the supplemental material and
Fig. 6B suggest that SV40 is released by a lytic mechanism, strong
cytopathic effects are rarely seen in BKPyV-infected cells. Inter-
estingly, a nonlytic directional release of SV40 from polarized pri-
mary African green monkey cells and Vero cells and a nonlytic
release of BKPyV from RPTECs has been reported (52, 53). Re-
cently nonlytic release has been demonstrated for several nonen-
veloped viruses, such as poliovirus, hepatitis A virus (HAV), par-
vovirus, and hepatitis E virus (reviewed in references 54 and 55).
These viruses seem to utilize autophagy or similar pathways to
release viral progeny enclosed in membranes without killing the
host cell, and the viral particles seem to be infectious with or with-
out the membrane. So far, there is no evidence for release of polyo-
mavirus enclosed in membranes, but it is possible that SV40 and
BKPyV can use both a lytic and a nonlytic pathway for release.
In conclusion, neither BKPyV nor SV40 requires VP4 for prog-
eny release from their natural host cells, but one conserved methi-
onine in VP2 seems important for viral replication, probably in-
fluencing viral entry or uncoating. Moreover, BKPyV needs both
VP2 and VP3 to form infectious viral particles.
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